NRM-823 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called NRM-823 to determine its safety and effectiveness for people with advanced or metastatic solid tumors, which are cancers that have spread or grown in place. The focus includes various types of cancer, such as certain lung, breast, and esophageal cancers. Participants must have a diagnosis of one of these cancers and be in relatively good physical condition, with no recent treatments that could interfere with the trial. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I need to stop my current medications for the trial?
The trial requires that you stop taking certain cancer treatments like chemotherapy, biologic agents, or radiation therapy at least 3 weeks before starting the study drug. However, it doesn't specify about other medications, so it's best to discuss with the trial team.
Is there any evidence suggesting that NRM-823 is likely to be safe for humans?
Research is currently testing NRM-823 for safety in treating advanced solid tumors. In this early stage, researchers focus primarily on its safety and patient tolerance. Detailed information on side effects or negative reactions is not yet available. At this phase, the emphasis remains on how patients handle the treatment. If NRM-823 is well-tolerated and does not cause major side effects, it would mark a positive step in its development.12345
Why do researchers think this study treatment might be promising?
Unlike the standard cancer treatments, which often involve chemotherapy or radiation, NRM-823 is unique because it targets cancer cells with a new mechanism of action. This innovative drug is designed to specifically interact with a particular protein found in cancer cells, potentially reducing harm to healthy cells and minimizing side effects. Researchers are excited about NRM-823 because it promises a more targeted approach, which could lead to more effective and less toxic cancer therapies.
What evidence suggests that NRM-823 might be an effective treatment for cancer?
Research shows that NRM-823, the treatment under study in this trial, has promising results in fighting cancer. Lab and animal studies have demonstrated its effectiveness in stopping tumor growth. This treatment uses T cells, part of the immune system, to attack cancer cells. Success in lab settings suggests it might help treat solid tumors in people. While these results are hopeful, further research is needed to confirm its effectiveness in cancer patients.12567
Who Is on the Research Team?
Melinda Merchant, MD, PhD
Principal Investigator
Normunity AccelCo, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with certain advanced or metastatic cancers, including lung, triple-negative breast, head and neck squamous cell, esophageal adenocarcinoma, stomach cancer, cervical cancer, endometrial cancer, and ovarian cancer. Participants must be in good physical condition (ECOG 0-1) and have proper liver, kidney, lung, heart function along with adequate blood counts.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Evaluation of the safety and tolerability of NRM-823
Treatment Part B
Further evaluation of safety and tolerability of NRM-823 at the recommended dose in an expansion cohort
Treatment Part C
Evaluation of the addition of a checkpoint inhibitor to NRM-823
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NRM-823
Find a Clinic Near You
Who Is Running the Clinical Trial?
Normunity AccelCo, Inc.
Lead Sponsor